ArticleDrug design, development and therapy2026
GLP-1 Receptor Agonists Versus DPP-4 Inhibitors and Incident Dementia Risk in COVID-19 Survivors with Type 2 Diabetes: A Target Trial Emulation Study.
Kuo-Chuan Hung et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.